Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus
Orhan Efe, … , Huiwen Ren, Jeff M. Sands
Orhan Efe, … , Huiwen Ren, Jeff M. Sands
Published July 21, 2016
Citation Information: JCI Insight. 2016;1(11):e88409. https://doi.org/10.1172/jci.insight.88409.
View: Text | PDF
Research Article Nephrology

Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus

  • Text
  • PDF
Abstract

Urine concentration is regulated by vasopressin. Congenital nephrogenic diabetes insipidus (NDI) is caused by vasopressin type 2 receptor (V2R) mutations. We studied whether metformin could improve urine concentration in rodent models of congenital NDI by stimulating AMPK. To block the V2R in rats, tolvaptan (10 mg/kg/d) was given by oral gavage with or without metformin (800 mg/kg/d). Control rats received vehicle with or without metformin. Tamoxifen-induced V2R KO mice were given metformin (600 mg/kg) or vehicle twice daily. Urine osmolality in tolvaptan-treated rats (1,303 ± 126 mOsM) was restored to control levels by metformin (2,335 ± 273 mOsM) within 3 days and was sustained for up to 10 days. Metformin increased protein abundance of inner medullary urea transporter UT-A1 by 61% and aquaporin 2 (AQP2) by 44% in tolvaptan-treated rats, and immunohistochemistry showed increased membrane accumulation of AQP2 with acute and chronic AMPK stimulation. Outer medullary Na+-K+-2Cl– cotransporter 2 (NKCC2) abundance increased (117%) with AMPK stimulation in control rats but not in V2R-blocked rats. Metformin increased V2R KO mouse urine osmolality within 3 hours, and the increase persisted for up to 12 hours. Metformin increased AQP2 in the V2R KO mice similar to the tolvaptan-treated rats. These results indicate that AMPK activators, such as metformin, might provide a promising treatment for congenital NDI.

Authors

Orhan Efe, Janet D. Klein, Lauren M. LaRocque, Huiwen Ren, Jeff M. Sands

×

Figure 1

Influence of metformin on urine-concentrating transporters.

Options: View larger image (or click on image) Download as PowerPoint
Influence of metformin on urine-concentrating transporters.
The nephron ...
The nephron is shown with 2 sections highlighted: the thick ascending limb and the inner medullary collecting duct (IMCD). In the thick ascending limb, metformin increases phosphorylation of the Na+-K+-2Cl– cotransporter 2 (NKCC2), activating it’s reabsorption of Na, K, and Cl into the cell. The Na-K-ATPase moves sodium into the interstitium at the basolateral membrane, ROMK returns K to the lumen. The net result is a movement of Na to the interstitium to increase interstitial hyperosmolality. In the IMCD, aquaporin 2 (AQP2) and urea transporter A1 (UT-A1) are phosphorylated and activated by AMPK and stimulated by metformin. They move water and urea into the IMCD cells, and AQP3 (and AQP4, not shown) and UT-A3 complete the transfer out of the cell into the interstitium.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts